• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

New chemotherapy precludes the need for radiotherapy in primary mediastinal B-cell lymphoma

bys25qthea
April 10, 2013
in Chronic Disease, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: PD

1. DA-EPOCH-R therapy achieved high rates of remission without radiotherapy. 

2. Patients receiving DA-EPOCH-R therapy maintained normal cardiac ejection fractions up to 10 years after treatment. 

Evidence Rating Level: 2 

Study Rundown: Subject to the limitations of a phase-II clinical trial, this study demonstrates that DA-EPOCH-R (dose-adjusted etoposide, doxorubicin, and cyclophosphamide with vincristine, prednisone and rituximab) therapy is safe and effective in treating primary mediastinal B-cell lymphoma in the absence of radiotherapy.

If further trials are successful, DA-EPOCH-R may represent a significant improvement over existing standards as it precludes radiotherapy and its attending side effects, such as secondary malignancies and atherosclerosis.

The sample size of 51 is too small to establish safety profiles. Compared to the de facto standard of R-CHOP chemotherapy, the only addition is etoposide, which itself has a well-established safety profile. Although unexpected drug-drug interactions are always a possibility, this phase-II study suggests that DA-EPOCH-R presents a safe alternative with the promise of high remission rates.

RELATED REPORTS

#VisualAbstract Ponatinib with FLAG-IDA is a feasible and active treatment strategy in patients with blast-phase chronic myeloid leukaemia

#VisualAbstract: Adjuvant capecitabine improves long-term survival in early breast cancer

Neoadjuvant nivolumab improves survival in patients with resectable non-small cell lung cancer

Click to read the study, published online today at NEJM 

Relevant Reading: Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamics approach with high efficacy

In-Depth [single group, prospective study]: This prospective study assessed the safety and efficacy of DA-EPOCH-R (dose-adjusted etoposide, doxorubicin, and cyclophosphamide with vincristine, prednisone and rituximab) in treating primary mediastinal B-cell lymphoma. All 51 eligible treatment-naĂŻve patients received DA-EPOCH-R plus filgrastim and were followed for disease progression and toxic effects. There was no control group. Additionally, the study examined retrospectively 16 patients who received DA-EPOCH-R therapy through a study at Stanford.

At a median follow-up of 63 months, the prospective group had event-free survival rates of 93% (95% confidence interval [CI], 81 to 98) with an overall survival of 97% (95% CI, 81 to 99). The retrospective Stanford cohort had 100% (95% CI, 79 to 100) survival and event-free rates over a median follow-up of 37 months.

The study measured ejection fractions in 42 patients to assess cardiac toxicity. All patients had normal ejection fractions up to 10 years post treatment. Additionally, thrombocytopenia (<25,000 platelets per cubic millimeter) occurred during 6% of cycles. Hospitalization for fever and neutropenia occurred during 13% of cycles.

By Xiaozhou Liu and Mitalee Patil

More from this author: Nonemergent perc. coronary intervention safe without on-site cardiac surgery services, Omalizumab relieves symptoms in difficult-to-treat chronic idiopathic urticaria, New device reduces acid exposure in gastroesophageal reflux disease, Neurostimulation beneficial in Parkinson’s disease with early motor complications, Rivaroxaban has no net clinical benefit over enoxaparin for thromboprophylaxis in acutely ill patients, Long term functional outcomes similar with surgery, radiotherapy in prostate cancer patients

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. Content is produced in accordance with fair use copyrights solely and strictly for the purpose of teaching, news and criticism. No benefit, monetary or otherwise, is realized by any participants or the owner of this domain. 

Tags: chemotherapyDA-EPOCH-R
Previous Post

Functional MRI map for physical pain identified

Next Post

Pediatric post-operative intussusception more common in open surgery

RelatedReports

#VisualAbstract Ponatinib with FLAG-IDA is a feasible and active treatment strategy in patients with blast-phase chronic myeloid leukaemia
StudyGraphics

#VisualAbstract Ponatinib with FLAG-IDA is a feasible and active treatment strategy in patients with blast-phase chronic myeloid leukaemia

June 12, 2022
#VisualAbstract: Adjuvant capecitabine improves long-term survival in early breast cancer
StudyGraphics

#VisualAbstract: Adjuvant capecitabine improves long-term survival in early breast cancer

May 18, 2022
Dacomitinib may be effective in EGFR-associated lung cancer
Chronic Disease

Neoadjuvant nivolumab improves survival in patients with resectable non-small cell lung cancer

May 9, 2022
#VisualAbstract: Neoadjuvant nivolumab plus chemotherapy increases event-free survival in resectable non-small-cell lung cancer
StudyGraphics

#VisualAbstract: Neoadjuvant nivolumab plus chemotherapy increases event-free survival in resectable non-small-cell lung cancer

April 28, 2022
Next Post
Pediatric post-operative intussusception more common in open surgery

Pediatric post-operative intussusception more common in open surgery

BRAF V600E mutations linked with increased mortality in thyroid cancer

BRAF V600E mutations linked with increased mortality in thyroid cancer

Everolimus only protects against early cardiac allograft vasculopathy

Everolimus only protects against early cardiac allograft vasculopathy

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Early exposure to allergenic foods may reduce incidence of long-term food allergy
  • Risk of post-vitrectomy endophthalmitis may have increased during the COVID-19 pandemic
  • Bosniak classification system differentiates benign renal cysts from cystic carcinoma [Classics Series]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.